Alzheimer's Disease Diagnostics

Global Alzheimer's Disease Diagnostics Market to Reach US$17.5 Billion by 2030

The global market for Alzheimer's Disease Diagnostics estimated at US$9.2 Billion in the year 2024, is expected to reach US$17.5 Billion by 2030, growing at a CAGR of 11.4% over the analysis period 2024-2030. Imaging Techniques, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Biomarkers segment is estimated at 10.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 15.6% CAGR

The Alzheimer's Disease Diagnostics market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Alzheimer`s Disease Diagnostics Market – Key Trends & Drivers Summarized

Why Is Early Diagnosis of Alzheimer’s Disease Gaining Critical Importance?
The early diagnosis of Alzheimer’s disease has become increasingly crucial as the global burden of neurodegenerative disorders continues to rise, with millions of individuals affected worldwide. The growing emphasis on early intervention is driven by the potential to slow disease progression, improve patient outcomes, and reduce healthcare costs associated with long-term care. Advances in diagnostic techniques are enabling healthcare professionals to identify Alzheimer`s disease at its earliest stages, even before significant cognitive decline occurs. Biomarker-based tests, neuroimaging techniques, and genetic screening methods have emerged as essential tools in detecting early signs of the disease, providing clinicians with valuable insights into the underlying pathology. The increasing awareness among healthcare providers and patients about the benefits of early diagnosis is also contributing to the growing demand for reliable and accurate diagnostic solutions.

The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic procedures is further revolutionizing the field, offering enhanced accuracy and efficiency in analyzing complex neurological data. AI-powered imaging analysis and predictive modeling are facilitating the early detection of subtle changes in brain structure and function, allowing for more personalized treatment approaches. Additionally, the rising adoption of non-invasive diagnostic methods, such as blood-based biomarkers and cerebrospinal fluid (CSF) tests, is making Alzheimer’s disease diagnosis more accessible and less burdensome for patients. As public health initiatives and advocacy groups continue to emphasize the importance of early detection, the market for Alzheimer`s disease diagnostics is expected to witness significant growth.

What Role Do Technological Advancements Play in Enhancing Diagnostic Accuracy?
Technological advancements are playing a transformative role in enhancing the accuracy, speed, and accessibility of Alzheimer`s disease diagnostics. The development of advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), has significantly improved the ability to visualize amyloid plaques and neurofibrillary tangles, which are key hallmarks of the disease. Innovations in radiotracer technologies have further enhanced the specificity of PET scans, enabling precise detection of beta-amyloid and tau protein accumulations in the brain. Additionally, the advent of fluid biomarker testing, including plasma-based assays and proteomics, has provided a less invasive and cost-effective alternative to traditional diagnostic methods, facilitating early and accurate diagnosis.

Next-generation sequencing (NGS) and other genomic profiling techniques have also revolutionized the landscape of Alzheimer`s disease diagnostics by identifying genetic risk factors associated with disease progression. Advances in multiplex biomarker platforms have allowed for simultaneous detection of multiple biomarkers, improving diagnostic sensitivity and specificity. Moreover, digital health technologies, such as wearable devices and remote monitoring tools, are enabling continuous tracking of cognitive and behavioral changes, providing valuable data for early intervention and disease management. As the demand for more reliable and efficient diagnostic solutions grows, ongoing research and development efforts are expected to yield even more sophisticated tools for Alzheimer`s disease detection and monitoring.

How Are Evolving Patient Preferences and Healthcare Trends Impacting the Market?
Evolving patient preferences and healthcare trends are reshaping the Alzheimer`s disease diagnostics market, with an increasing focus on personalized and patient-centric approaches. Patients and caregivers are becoming more proactive in seeking early diagnostic options, driven by growing awareness of the disease and its impact on quality of life. The rising preference for non-invasive and home-based diagnostic solutions has led to the development of point-of-care testing kits and digital cognitive assessment tools that provide quick and convenient results. Furthermore, the integration of telemedicine services has enabled patients in remote and underserved areas to access diagnostic services, expanding market reach and improving early detection rates.

Healthcare providers are also adopting a more holistic approach to Alzheimer`s diagnosis, incorporating cognitive testing, behavioral assessments, and lifestyle risk evaluations alongside traditional biomarker tests. The emphasis on multi-modal diagnostic strategies is helping to provide a comprehensive understanding of the disease, allowing for tailored treatment plans and personalized care strategies. In addition, the growing collaboration between diagnostic companies, pharmaceutical firms, and research institutions is fostering innovation and accelerating the development of novel diagnostic solutions. As the healthcare ecosystem continues to evolve, the Alzheimer`s disease diagnostics market is poised to benefit from increased patient engagement and the growing demand for accessible and accurate testing options.

What Are the Key Factors Driving the Growth of the Alzheimer’s Disease Diagnostics Market?
The growth in the Alzheimer`s disease diagnostics market is driven by several factors, including advancements in diagnostic technologies, increasing awareness about the importance of early detection, and the rising prevalence of the disease due to an aging population. The rapid development of biomarker-based tests and imaging techniques is improving diagnostic accuracy, while the adoption of AI-powered solutions is enhancing efficiency and reducing diagnostic turnaround times. The expanding application of fluid biomarkers and genetic testing is also contributing to market growth, offering clinicians more precise tools for disease risk assessment and monitoring. Furthermore, the growing demand for non-invasive and cost-effective diagnostic solutions is driving innovation in at-home testing kits and digital health platforms, catering to evolving consumer preferences. Government initiatives and funding for Alzheimer’s research, coupled with strategic collaborations among healthcare stakeholders, are further propelling market expansion. As the focus on early intervention and personalized medicine continues to grow, the Alzheimer’s disease diagnostics market is expected to witness sustained development and widespread adoption across various healthcare settings.

SCOPE OF STUDY:

The report analyzes the Alzheimer's Disease Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Diagnostics Technique (Imaging Techniques, Biomarkers, Cognitive Assessment Tests, Genetic Testing); Product Type (Diagnosis Products, Triage Products, Screening Products); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Alector, Inc.
• Bristol-Myers Squibb Company
• C2N Diagnostics LLC
• Cognition Therapeutics
• F. Hoffmann-La Roche AG
• Fujirebio Inc.
• Laboratory Corporation of America Holdings
• Quanterix Corporation
• Quest Diagnostics, Inc.
• Siemens Healthineers
• Sysmex Corporation
• Treventis Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.